X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (86) 86
hygiene (86) 86
medical or veterinary science (86) 86
preparations for medical, dental, or toilet purposes (86) 86
specific therapeutic activity of chemical compounds ormedicinal preparations (76) 76
humans (37) 37
female (30) 30
index medicus (27) 27
middle aged (25) 25
oncology (24) 24
male (22) 22
aged (21) 21
adult (19) 19
investigating or analysing materials by determining theirchemical or physical properties (15) 15
measuring (15) 15
physics (15) 15
testing (15) 15
sirolimus - analogs & derivatives (14) 14
chemistry (13) 13
metallurgy (13) 13
research (12) 12
antineoplastic agents - therapeutic use (11) 11
cancer (11) 11
treatment outcome (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
beer (9) 9
biochemistry (9) 9
care and treatment (9) 9
compositions or test papers therefor (9) 9
condition-responsive control in microbiological orenzymological processes (9) 9
enzymology (9) 9
measuring or testing processes involving enzymes, nucleicacids or microorganisms (9) 9
microbiology (9) 9
mutation or genetic engineering (9) 9
processes of preparing such compositions (9) 9
sirolimus - administration & dosage (9) 9
sirolimus - therapeutic use (9) 9
spirits (9) 9
vinegar (9) 9
wine (9) 9
aged, 80 and over (8) 8
disease-free survival (8) 8
organic chemistry (8) 8
sirolimus - adverse effects (8) 8
carcinoma, renal cell - drug therapy (7) 7
dose-response relationship, drug (7) 7
kidney neoplasms - drug therapy (7) 7
peptides (7) 7
analysis (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
cardiovascular-disease (6) 6
growth (6) 6
risk factors (6) 6
temsirolimus (6) 6
type 2 diabetes (6) 6
antineoplastic agents - administration & dosage (5) 5
carcinoma, renal cell (5) 5
cci-779 (5) 5
chemotherapy (5) 5
clinical trials (5) 5
drug administration schedule (5) 5
drug therapy (5) 5
mammalian target (5) 5
maximum tolerated dose (5) 5
mtor (5) 5
obstetrics & gynecology (5) 5
prognosis (5) 5
antineoplastic agents - pharmacokinetics (4) 4
carcinoma, renal cell - mortality (4) 4
carcinoma, renal cell - pathology (4) 4
cardiovascular diseases (4) 4
cohort studies (4) 4
complications and side effects (4) 4
hematology (4) 4
kidney neoplasms - mortality (4) 4
kidney neoplasms - pathology (4) 4
medical research (4) 4
metaanalysis (4) 4
mortality (4) 4
neoplasm staging (4) 4
neoplasms - drug therapy (4) 4
original reports (4) 4
ovarian cancer (4) 4
ovarian neoplasms - drug therapy (4) 4
ovarian neoplasms - pathology (4) 4
paclitaxel (4) 4
prevention (4) 4
signal transduction - drug effects (4) 4
sirolimus - pharmacokinetics (4) 4
survival analysis (4) 4
tor serine-threonine kinases (4) 4
trial (4) 4
administration, oral (3) 3
adolescent (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antitumor-activity (3) 3
article (3) 3
association (3) 3
blood-pressure (3) 3
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (139) 139
French (24) 24
German (14) 14
Chinese (10) 10
Japanese (9) 9
Spanish (7) 7
Korean (5) 5
Portuguese (4) 4
Hungarian (3) 3
Croatian (2) 2
Danish (2) 2
Greek (2) 2
Slovenian (2) 2
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3822 - 3829
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 30, pp. 3791 - 3799
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 2, pp. 68 - 75
Purpose Human epidermal growth factor (HER) -mediated signaling is critical in many cancers, including subsets of breast and lung cancer. HER family members... 
CELL LUNG-CANCER | HKI-272 | THERAPY | TRASTUZUMAB | ONCOLOGY | METASTATIC BREAST-CANCER | TYROSINE KINASE INHIBITOR | HER2 STATUS | MUTATIONS | EXPRESSION | EGFR | Neoplasms - metabolism | Lung Neoplasms - drug therapy | Nausea - chemically induced | Receptor, ErbB-2 - genetics | TOR Serine-Threonine Kinases - metabolism | Area Under Curve | Humans | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Phosphatidylinositol 3-Kinases - metabolism | Diarrhea - chemically induced | Quinolines - administration & dosage | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Quinolines - pharmacokinetics | Neoplasms - genetics | Female | Sirolimus - adverse effects | Lung Neoplasms - genetics | Sirolimus - analogs & derivatives | Anemia - chemically induced | Treatment Outcome | Sirolimus - pharmacokinetics | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Sirolimus - administration & dosage | Breast Neoplasms - genetics | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Mutation | Quinolines - adverse effects | Index Medicus
Journal Article
Annual Review of Medicine, ISSN 0066-4219, 01/2018, Volume 69, p. 191
The concept of exploiting the specific binding properties of monoclonal antibodies as a mechanism for selective delivery of cytotoxic agents to tumor cells is... 
Antigens | Medical research | Tumor cells | Clinical trials | Cytotoxicity | Breast cancer | Pharmacology | Chemical compounds | Cell surface | ErbB-2 protein | Lymphoma | Cells | Metastases | Anticancer properties | Monoclonal antibodies | Lymphomas | Anaplastic large-cell lymphoma | Solid tumors | Cytotoxic agents | Hodgkin's disease | Trastuzumab | Tumors | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5601 - 5606
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2933 - 2940
Purpose To determine dose-limiting toxicities, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of weekly intravenous temsirolimus, a... 
MAMMALIAN TARGET | BREAST-CANCER | SINGLE-AGENT | ONCOLOGY | PRECLINICAL MODELS | GROWTH | RHABDOMYOSARCOMA CELLS | RAPAMYCIN ANALOG CCI-779 | RENAL-CELL CARCINOMA | CANCER-THERAPY | MTOR INHIBITOR | Phosphorylation | TOR Serine-Threonine Kinases - metabolism | United States | Humans | Child, Preschool | Infant | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphoproteins - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Proto-Oncogene Proteins c-akt - metabolism | Child | Sirolimus - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Drug Administration Schedule | Neoplasms - enzymology | Treatment Outcome | Sirolimus - pharmacokinetics | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Maximum Tolerated Dose | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Ribosomal Protein S6 - metabolism | Adolescent | Infusions, Intravenous | Adaptor Proteins, Signal Transducing - metabolism | Neoplasms - pathology | Index Medicus | Faze | Pedi10 | Original Reports | Pedi6 | Pedi12 | Pedi25 | Pedi16
Journal Article
Journal Article